Text Size

Topical Antimicrobial Effectiveness Testing

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CareFusion
ClinicalTrials.gov Identifier:
NCT01314703
First received: March 10, 2011
Last updated: October 30, 2012
Last verified: October 2012
History of Changes
  Purpose

The primary objective of this study is to measure the antimicrobial effectiveness of ChloraPrep one-Step.


Condition Intervention Phase
Antimicrobial Effectiveness
 Drug: ChloraPrep One-Step
Drug: 70% isopropyl alcohol
 Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Official Title: Test for Preoperative Skin Preparations

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by CareFusion:

Primary Outcome Measures:
  • Antimicrobial Efficacy Will be Measured by the Change (+/-) in Bacterial Count on the Skin 10 Minutes After a Single Application of Test Material Relative to the Baseline Bacterial Count. [ Time Frame: 10 minutes after single application of test material ] [ Designated as safety issue: No ]
    the measure of antimicrobial efficacy was calculated by subtracting the 10 minute post test material application bacterial recovery from the baseline bacterial recovery.


Enrollment: 27
Study Start Date: March 2011
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ChloraPrep One-Step
    10.5 ml applicator preoperative skin preparation
    Drug: 70% isopropyl alcohol
    10.5 ml applicator
    Other Name: Positive control
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • in good general health
  • have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders.

Exclusion Criteria:

  • topical or systemic antimicrobial exposure within 14 days prior to Screening Day
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314703

Locations
United States, Virginia
Microbiotest
Sterling, Virginia, United States, 20164
Sponsors and Collaborators
CareFusion
Investigators
Principal Investigator: Muhammad H Bashir, MD Microbiotest
  More Information

No publications provided

Responsible Party: CareFusion
ClinicalTrials.gov Identifier: NCT01314703     History of Changes
Other Study ID Numbers: 371.1.02.15.11
Study First Received: March 10, 2011
Results First Received: February 8, 2012
Last Updated: October 30, 2012
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on May 19, 2013